|
|
|
|
Nevada
|
|
001-37471
|
|
30-0784346
|
(State or other jurisdiction of
incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
255 State Street, 9th Floor
Boston, MA
(Address of principal executive offices)
|
|
|
|
02109
(Zip Code)
|
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
|
|
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, $0.001 par value per share
|
|
PIRS
|
|
The Nasdaq Capital Market
|
|
|
PIERIS PHARMACEUTICALS, INC.
|
|
|
|
Dated: June 8, 2020
|
|
/s/ Tom Bures
|
|
|
Tom Bures
|
|
|
Vice President, Finance
|